Cargando…
Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study)
INTRODUCTION: Mirogabalin, which is a selective ligand of the α(2)δ subunit of voltage-gated Ca(2+) channels, was recently approved in Japan for peripheral neuropathic pain. The α(2)δ ligands, including mirogabalin and pregabalin, are associated with significant risk of adverse events (AEs) such as...
Autores principales: | Kimura, Yoshiyuki, Yamaguchi, Shigeki, Suzuki, Takahiro, Kato, Jitsu, Chiba, Satoko, Hirakawa, Naomi, Yamaguchi, Keisuke, Tanabe, Yutaka, Takatsuna, Hiroshi, Kenyoshi, Yusuke, Shiosakai, Kazuhito, Sakai, Miyoshi, Iseki, Masako |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119591/ https://www.ncbi.nlm.nih.gov/pubmed/33856660 http://dx.doi.org/10.1007/s40122-021-00255-y |
Ejemplares similares
-
Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022) -
Correction to: Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022) -
Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
por: Doi, Ryoichiro, et al.
Publicado: (2021) -
Mirogabalin: could it be the next generation gabapentin or pregabalin?
por: Kim, Jae-Yeon, et al.
Publicado: (2021) -
Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin
por: Yamanaka, Takuya, et al.
Publicado: (2022)